Corcept Therapeutics (CORT) CBO logs stock grants and tax withholding in Form 4

Rhea-AI Filing Summary

Corcept Therapeutics’ Chief Business Officer Gary Charles Robb reported routine equity compensation activity in the company’s common stock. On March 2, 2026, he acquired 499 shares at $35.97 per share under a purchase plan established pursuant to the 2024 Incentive Award Plan, and received an additional 499-share restricted stock award at no stated cost. These awards include unvested restricted stock that will fully vest on the one-year anniversary of each grant if specified service and ownership conditions are met.

On March 3, 2026, 121 shares were disposed of at $35.97 per share to satisfy tax withholding obligations tied to vesting restricted stock units, meaning the shares were withheld by the company rather than sold in the open market. After these transactions, Robb directly held 79,503 shares and indirectly oversaw 11,571 shares held in a custodial account for a child under the Uniform Transfers to Minors Act.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Robb Gary Charles

(Last) (First) (Middle)

C/O CORCEPT THERAPEUTICS INCORPORATED

101 REDWOOD SHORES PARKWAY

(Street)

REDWOOD CITY CA 94065

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CORCEPT THERAPEUTICS INC [ CORT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Business Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/02/2026		A		499(1)	A	$35.97(2)	79,125(3)	D
Common Stock	03/02/2026		A		499(4)	A	$0	79,624(3)	D
Common Stock	03/03/2026		F(5)		121	D	$35.97(6)	79,503(7)	D
Common Stock								11,571	I	Custodial Account for Child(8)
Common Stock								11,571	I	Custodial Account for Child(9)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on March 2, 2026.

2. In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase.

3. Includes 292 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025, 997 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025, 251 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025 and 224 share underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

4. Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary.

5. These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units.

6. The closing price on March 2, 2026 was used to calculate the withholding obligation.

7. Includes 997 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025, and 251 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025 and 224 share underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

8. These shares are held by a child of the Reporting Person through a custodial account under the Uniform Transfers to Minors Act for which the Reporting Person is custodian.

9. These shares are held by a child of the Reporting Person through a custodial account under the Uniform Transfers to Minors Act for which the Reporting Person is custodian.

Remarks:

The power of attorney under which this form was signed is on file with the Commission.

	/s/ Joseph Douglas Lyon, as attorney-in-fact for Gary Charles Robb.	03/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Corcept Therapeutics (CORT) report for Gary Charles Robb?

Corcept Therapeutics reported that Chief Business Officer Gary Charles Robb received two equity grants totaling 998 common shares on March 2, 2026, and had 121 shares withheld on March 3, 2026 to cover tax obligations from vesting restricted stock units.

How many Corcept Therapeutics shares did Gary Charles Robb acquire in the latest Form 4?

Gary Charles Robb acquired 499 common shares at $35.97 per share under a purchase plan and an additional 499-share restricted stock award on March 2, 2026, reflecting routine equity compensation rather than open-market buying activity in Corcept Therapeutics stock.

Why were 121 Corcept Therapeutics shares disposed of in Gary Charles Robb’s Form 4?

The 121-share disposition was for tax withholding. Corcept Therapeutics withheld these shares at $35.97 per share on March 3, 2026 to satisfy Robb’s tax obligations from vesting restricted stock units, rather than an open-market sale initiated by him.

What is Gary Charles Robb’s Corcept Therapeutics share ownership after these transactions?

Following the reported transactions, Gary Charles Robb directly owned 79,503 Corcept Therapeutics common shares. In addition, 11,571 shares were held indirectly in a custodial account for his child under the Uniform Transfers to Minors Act, where he serves as custodian.

How do vesting conditions work for Gary Charles Robb’s Corcept restricted stock awards?

The restricted stock awards will vest 100% on the one-year anniversary of each grant date. Vesting requires that Robb meet specified service or ownership conditions, including remaining the beneficial owner of certain purchase plan shares for one year, as described in the Form 4 footnotes.

What is the purchase plan mentioned in Corcept Therapeutics’ Form 4 for Gary Charles Robb?

The purchase plan is established under Corcept Therapeutics’ 2024 Incentive Award Plan. On March 2, 2026, Robb purchased common stock under this plan at the closing price of $35.97 per share, with the price determined in accordance with the plan’s terms.